Breaking Finance News

A statement released earlier today by Vetr Inc. about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) bumps the target price to $14.82

Boasting a price of $13.45, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) traded -0.50% lower on the day. With the last close down -11.79% from the two hundred day average, compared with the S&P 500 Index which has increased 0.01% over the date range. Valeant Pharmaceuticals Intl Inc has recorded a 50-day average of $13.70 and a two hundred day average of $13.67. Volume of trade was down over the average, with 9,602,318 shares of VRX changing hands under the typical 11,819,600

Vetr Inc. bumped up the target of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to $14.82 stating a potential upside of 0.10%.

On Thursday May 18, 2017, Stifel Nicolaus released a statement on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) bumped down the target price from $45.00 to $35.00 that suggested an upside of 1.58%.

Performance Chart

Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

With a total market value of $0, Valeant Pharmaceuticals Intl Inc has with a one year low of $8.31 and a one year high of $24.30 .

A total of 18 analysts have released a research note on VRX. Three analysts rating the company a strong buy, two analysts rating the company a buy, ten analysts rating the company a hold, four analysts rating the company a underperform, and finally one analyst rating the company a sell with a one year target of $43.56.

More About Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.